Actively Recruiting
Remibrutinib Open Label Roll-over Post-trial Access Protocol
Led by Novartis Pharmaceuticals · Updated on 2026-05-12
212
Participants Needed
3
Research Sites
354 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Multi-center, open-label roll-over post-trial access protocol to provide remibrutinib treatment and collect long-term safety for up to three years for participants who are currently receiving remibrutinib treatment in a Novartis-sponsored study, who are benefiting from treatment with remibrutinib, and are unable to access remibrutinib treatment outside of a clinical study.
CONDITIONS
Official Title
Remibrutinib Open Label Roll-over Post-trial Access Protocol
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant has completed treatment per protocol in a Novartis study of remibrutinib in dermatological or allergology indications
- Participants benefiting from remibrutinib but unable to access it outside clinical studies
- Investigator believes participant continues to benefit and benefits outweigh risks
- Participant cannot obtain marketed remibrutinib through local programs or prescription/reimbursement guidelines
You will not qualify if you...
- Participant prematurely discontinued remibrutinib treatment in the parent study
- Use of prohibited medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Novartis Investigative Site
London, Ontario, Canada, N6H 5L5
Actively Recruiting
2
Novartis Investigative Site
Daegu, Dalseo Gu, South Korea, 42602
Actively Recruiting
3
Novartis Investigative Site
Gwangju, South Korea, 61469
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here